These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist. Chang KL; Wong LR; Pee HN; Yang S; Ho PC Mol Neurobiol; 2019 Nov; 56(11):7267-7283. PubMed ID: 31016475 [TBL] [Abstract][Full Text] [Related]
5. p110δ PI3-Kinase Inhibition Perturbs APP and TNFα Trafficking, Reduces Plaque Burden, Dampens Neuroinflammation, and Prevents Cognitive Decline in an Alzheimer's Disease Mouse Model. Martínez-Mármol R; Mohannak N; Qian L; Wang T; Gormal RS; Ruitenberg MJ; Vanhaesebroeck B; Coulson EJ; Meunier FA J Neurosci; 2019 Oct; 39(40):7976-7991. PubMed ID: 31363064 [TBL] [Abstract][Full Text] [Related]
6. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. Nicolakakis N; Aboulkassim T; Ongali B; Lecrux C; Fernandes P; Rosa-Neto P; Tong XK; Hamel E J Neurosci; 2008 Sep; 28(37):9287-96. PubMed ID: 18784309 [TBL] [Abstract][Full Text] [Related]
7. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer's disease: in vitro and in vivo studies. Silva-Abreu M; Calpena AC; Andrés-Benito P; Aso E; Romero IA; Roig-Carles D; Gromnicova R; Espina M; Ferrer I; García ML; Male D Int J Nanomedicine; 2018; 13():5577-5590. PubMed ID: 30271148 [TBL] [Abstract][Full Text] [Related]
8. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice. Feng J; Wang JX; Du YH; Liu Y; Zhang W; Chen JF; Liu YJ; Zheng M; Wang KJ; He GQ CNS Neurosci Ther; 2018 Dec; 24(12):1207-1218. PubMed ID: 29869390 [TBL] [Abstract][Full Text] [Related]
9. Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice. Liu D; Zhao Y; Qi Y; Gao Y; Tu D; Wang Y; Gao HM; Zhou H J Neuroinflammation; 2020 Aug; 17(1):258. PubMed ID: 32867800 [TBL] [Abstract][Full Text] [Related]
10. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease. Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037 [TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal Administration of Monoclonal Antibody Against Pathologic Aβ42 Aggregates Alleviated Cognitive Deficits and Synaptic Lesions in APP/PS1 Mice. Xiao S; Song LL; Li JT; Wang H; Yu N; Wang ZQ; Zhang Y; He JS; Hung T J Alzheimers Dis; 2020; 73(2):657-670. PubMed ID: 31839610 [TBL] [Abstract][Full Text] [Related]
12. Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Liu LP; Yan TH; Jiang LY; Hu W; Hu M; Wang C; Zhang Q; Long Y; Wang JQ; Li YQ; Hu M; Hong H Acta Pharmacol Sin; 2013 Apr; 34(4):455-63. PubMed ID: 23524568 [TBL] [Abstract][Full Text] [Related]
13. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Naert G; Rivest S J Neurosci; 2011 Apr; 31(16):6208-20. PubMed ID: 21508244 [TBL] [Abstract][Full Text] [Related]
14. Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Guo HB; Cheng YF; Wu JG; Wang CM; Wang HT; Zhang C; Qiu ZK; Xu JP Neuroscience; 2015 Apr; 290():530-42. PubMed ID: 25662507 [TBL] [Abstract][Full Text] [Related]
15. Bulbocodin D ameliorate cognitive impairment in APP/PS1 transgenic mice by modulating amyloid-beta burden, oxidative status and neuroinflammation. Hao F; Feng Y Psychopharmacology (Berl); 2021 Aug; 238(8):2073-2082. PubMed ID: 33811504 [TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV, a Natural PPARγ Agonist, Reduces Aβ Production in Alzheimer's Disease Through Inhibition of BACE1. Wang X; Wang Y; Hu JP; Yu S; Li BK; Cui Y; Ren L; Zhang LD Mol Neurobiol; 2017 May; 54(4):2939-2949. PubMed ID: 27023226 [TBL] [Abstract][Full Text] [Related]
17. Valproic acid reduces neuritic plaque formation and improves learning deficits in APP(Swe) /PS1(A246E) transgenic mice via preventing the prenatal hypoxia-induced down-regulation of neprilysin. Wang Z; Zhang XJ; Li T; Li J; Tang Y; Le W CNS Neurosci Ther; 2014 Mar; 20(3):209-17. PubMed ID: 24289518 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. Mandrekar-Colucci S; Karlo JC; Landreth GE J Neurosci; 2012 Jul; 32(30):10117-28. PubMed ID: 22836247 [TBL] [Abstract][Full Text] [Related]
19. Cerebral inoculation of human A53T α-synuclein reduces spatial memory decline and amyloid-β aggregation in APP/PS1 transgenic mice of Alzheimer's disease. Hao YN; Lu QX; Zhai YH; Wang HY; Wu MN; Hu MM; Yang B; Wang ZJ; Wu ZW; Qi JS Brain Res Bull; 2018 Oct; 143():116-122. PubMed ID: 30366065 [TBL] [Abstract][Full Text] [Related]
20. Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer's disease mouse model with suppression of glymphatic clearance. Feng W; Zhang Y; Wang Z; Xu H; Wu T; Marshall C; Gao J; Xiao M Alzheimers Res Ther; 2020 Oct; 12(1):125. PubMed ID: 33008458 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]